The goal of this project is to obtain a new sensitive and specific biomarker of myelin/axonal integrity, valid in both inflammatory and non-inflammatory settings. We will do this by combining the myelin-related properties (as obtained by modeling the relaxometry MRI data ) and the axonal structure and orientation-related information derived by modeling the diffusion MRI signal. The ultimate aim of this project is to provide personalized measures of myelin and axonal integrity, to develop a new patient-tailored way to optimize individual patient treatment strategy.
To date, MRI is the reference neuroimaging modality used in MS assessment. Yet, due to its intrinsic disseminated essence, the processes linked to MS pathology have been difficult to visualize using conventional in-vivo imaging techniques, which are limited by low pathological specificity and low sensitivity to diffuse damage. Quantitative MRI techniques offer complementary information about the different components of brain tissue architecture. All of them have proven to be extremely sensitive to specific tissue abnormalities, albeit at the price of poor specificity. Combining the recent advances in qMRI using multimodal approaches may provide new biomarkers of disease severity and help to improve the clinical–radiological mismatch in MS treatment.